Primary cutaneous adenoid cystic carcinoma (PCACC) isa rare skin malignancy first reported in the 1970s with limited number of cases found in the literature. These neoplasms are typically identified in middle-to-older-age individuals and are mostly located in the scalp and neck region but can identified throughout the body. We describe the case of a 67-year-old male patient that presented to our department with a slow-growing nodule in the left gluteal region that turned out to be a PCACC and analyze the differential diagnosis, radiology, histopathological findings and successful treatment with a wide local excision. Current literature on the subject is also presented and discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3390/diagnostics15050533 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Skin cancer is the most commonly diagnosed malignancy in the United States, costing more than $8.1 billion annually in treatment-related expenses, yet with ultraviolet exposure considered the most significant risk factor for skin cancer development, cutaneous malignancy is also highly preventable. The Affordable Care Act (ACA) is committed to covering demonstrably effective preventive health care measures without patient cost sharing.
View Article and Find Full Text PDFA Rare Case of Primary Cutaneous Adenoid Cystic Carcinoma.
Diagnostics (Basel)
February 2025
Department of General Surgery, General Hospital of Katerini, 60100 Katerini, Greece.
Primary cutaneous adenoid cystic carcinoma (PCACC) isa rare skin malignancy first reported in the 1970s with limited number of cases found in the literature. These neoplasms are typically identified in middle-to-older-age individuals and are mostly located in the scalp and neck region but can identified throughout the body. We describe the case of a 67-year-old male patient that presented to our department with a slow-growing nodule in the left gluteal region that turned out to be a PCACC and analyze the differential diagnosis, radiology, histopathological findings and successful treatment with a wide local excision.
View Article and Find Full Text PDFEffectiveness and Toxicity of Cemiplimab Therapy for Advanced Cutaneous Squamous Cell Skin Cancer in a Community Oncology Practice.
Cancers (Basel)
February 2025
Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA.
Background: The immune checkpoint inhibitor cemiplimab has significant clinical activity in unresectable and metastatic cutaneous squamous cell carcinomas. There are limited real-world data available to assess the outcome of cemiplimab treatment in patients in a community practice setting.
Methods: We conducted a retrospective analysis of treatment outcomes following cemiplimab treatment (350 mg IV every 3 weeks) of squamous cell skin cancer.
Primary cutaneous/subcutaneous Ewings sarcoma.
Bull Cancer
March 2025
Pediatric Oncology, insitut Gustave-Roussy, Villejuif, France. Electronic address:
Amongst Ewing sarcoma family of tumours, (EFST), cutaneous/subcutaneous Ewing sarcoma are defined as tumours arising from cutaneous or subcutaneous tissue, not invading the underlying aponeurosis. They are rare tumours, with less than 200 patients published. They are typically small tumours (less than 5cm), and can arise at any anatomical location, with a particular tropism for distal, truncal and head/neck locations, compared to classical Ewing sarcoma.
View Article and Find Full Text PDFIn-transit melanoma metastases: Evaluation and Management for the Dermatologist.
J Am Acad Dermatol
March 2025
Mayo Clinic, Department of Dermatology, Rochester, MN, USA. Electronic address:
In-transit metastases (ITM) are estimated to occur in 5-10% of primary cutaneous melanomas. They are classified as stage III disease in the American Joint Committee on Cancer classification system and are associated with approximately a 30% 10-year survival rate. The management of ITM is not standardized.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!